• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Acer Therapeutics Inc. (Amendment)

    2/14/22 8:00:12 AM ET
    $ACER
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACER alert in real time by email
    SC 13G/A 1 tm222623d1_sc13ga.htm SCHEDULE 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 3)*

     

    Acer Therapeutics Inc.

    (Name of Issuer)

     

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

     

    00444P108

    (CUSIP Number)

     

    December 31, 2021

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    ¨ Rule 13d-1(c)

    ¨ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    Continued on following pages

    Page 1 of 7 Pages

     

     

     

     

     

    CUSIP NO. 00444P108Page 2 of 7

     

    CUSIP No.  00444P108
    (1) Names of reporting persons Nantahala Capital Management, LLC
    (2) Check the appropriate box if a member of a group (a) ¨
    (see instructions) (b) ¨
    (3) SEC use only  
    (4) Citizenship or place of organization MA
    Number of shares beneficially owned by each reporting person with:  
    (5) Sole voting power 0
    (6) Shared voting power 901,290
    (7) Sole dispositive power 0
    (8) Shared dispositive power 901,290
    (9) Aggregate amount beneficially owned by each reporting person 901,290
    (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions)  
    (11) Percent of class represented by amount in Row (9) 6.3%
    (12) Type of reporting person (see instructions) IA

     

     

     

    CUSIP NO. 00444P108Page 3 of 7

     

    CUSIP No.  00444P108
    (1) Names of reporting persons Wilmot B. Harkey
    (2) Check the appropriate box if a member of a group (a) ¨
    (see instructions) (b) ¨
    (3) SEC use only  
    (4) Citizenship or place of organization USA
    Number of shares beneficially owned by each reporting person with:  
    (5) Sole voting power 0
    (6) Shared voting power 901,290
    (7) Sole dispositive power 0
    (8) Shared dispositive power 901,290
    (9) Aggregate amount beneficially owned by each reporting person 901,290
    (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions)  
    (11) Percent of class represented by amount in Row (9) 6.3%
    (12) Type of reporting person (see instructions) HC

     

     

     

    CUSIP NO. 00444P108Page 4 of 7

     

    CUSIP No.  00444P108
    (1) Names of reporting persons Daniel Mack
    (2) Check the appropriate box if a member of a group (a) ¨
    (see instructions) (b) ¨
    (3) SEC use only  
    (4) Citizenship or place of organization USA
    Number of shares beneficially owned by each reporting person with:  
    (5) Sole voting power 0
    (6) Shared voting power 901,290
    (7) Sole dispositive power 0
    (8) Shared dispositive power 901,290
    (9) Aggregate amount beneficially owned by each reporting person 901,290
    (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions)  
    (11) Percent of class represented by amount in Row (9) 6.3%
    (12) Type of reporting person (see instructions) HC

     

    Item 1(a). Name of Issuer:
       
      Acer Therapeutics Inc. (the “Issuer”).
       
    Item 1(b). Address of the Issuer's Principal Executive Offices:
       
      One Gateway Center, Suite 351, 300 Washington Street, Newton, MA 02458
       
    Item 2(a). Name of Person Filing
       
     

    Nantahala Capital Management, LLC (“Nantahala”)

    Wilmot B. Harkey

    Daniel Mack (together the “Reporting Persons”)

       
    Item 2(b). Address of Principal Business Office or, if None, Residence:
       
     

    130 Main St. 2nd Floor

    New Canaan, CT 06840

     

    Item 2(c). Citizenship:
       
     

    Nantahala is a Massachusetts limited liability company.

    Each of Messrs. Harkey and Mack is a citizen of the United States of America.

       
    Item 2(d).

    Title of Class of Securities:

     

     

    Common Stock, $0.0001 par value per share (the “Shares”). 

     

     

     

    CUSIP NO. 00444P108Page 5 of 7

     

     

    Item 2(e).

    CUSIP Number:
     

     

    00444P108

     


    Item 3.

    If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

     

     

    (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

    (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).

     

    (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

     

    (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).

     

    (g) x A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G).

     

    (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

     

    (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).

     

    (j) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(J).

     

    Item 4.

     

    Ownership:

       
    Item 4(a).

    Amount Beneficially Owned:

     

    As of December 31, 2021, Nantahala may be deemed to be the beneficial owner of 901,290 Shares held by funds and separately managed accounts under its control, and as the managing members of Nantahala, each of Messrs. Harkey and Mack may be deemed to be a beneficial owner of those Shares.

       
    Item 4(b).

    Percent of Class:

     

    As of December 31, 2021, each of the Reporting Persons may be deemed to be the beneficial owner of 6.3% of the total number of Shares outstanding (based upon information provided by the Issuer on Form 10-Q filed November 19, 2021, there were 14,310,244 Shares outstanding as of November 1, 2021).

     

     

     

    CUSIP NO. 00444P108Page 6 of 7

     

    Item 4(c). Number of shares as to which such person has:
       
     

    Nantahala Capital Management, LLC

     

      (i) Sole power to vote or direct the vote 0
      (ii) Shared power to vote or to direct the vote 901,290
      (iii) Sole power to dispose or to direct the disposition of 0
      (iv) Shared power to dispose or to direct the disposition of 901,290
     

    Each of Messrs. Harkey and Mack

     

      (i) Sole power to vote or direct the vote 0
      (ii) Shared power to vote or to direct the vote 901,290
      (iii) Sole power to dispose or to direct the disposition of 0
      (iv) Shared power to dispose or to direct the disposition of 901,290
    Item 5. Ownership of Five Percent or Less of a Class:
       
      This Item 5 is not applicable.
       
    Item 6. Ownership of More than Five Percent on Behalf of Another Person:
       
      This Item 6 is not applicable.
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company:
       
      Each of Messrs. Harkey and Mack is filing this Schedule 13G as a control person in respect of shares beneficially owned by Nantahala, an investment adviser as described in §240.13d-1(b)(1)(ii)(E).  See Item 4(a).
       
    Item 8. Identification and Classification of Members of the Group:
       
      This Item 8 is not applicable.
       
    Item 9. Notice of Dissolution of Group:
       
      This Item 9 is not applicable.
       
    Item 10. Certification:
       
    By signing below each Reporting Person certifies that, to the best of such person's knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect. 

     

     

     

    CUSIP NO. 00444P108Page 7 of 7

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete, and correct.

     

    Date:  February 14, 2022 NANTAHALA CAPITAL MANAGEMENT, LLC
       
      By:        /s/ Taki Vasilakis                                            
      Taki Vasilakis
      Chief Compliance Officer
       
      /s/ Wilmot B. Harkey
      Wilmot B. Harkey
       
      /s/ Daniel Mack
      Daniel Mack

     

     

    Get the next $ACER alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ACER

    DatePrice TargetRatingAnalyst
    2/2/2022$9.00Buy
    EF Hutton
    More analyst ratings

    $ACER
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Aselage Steve returned 483,741 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Acer Therapeutics Inc. (0001069308) (Issuer)

      11/20/23 5:09:40 PM ET
      $ACER
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dunn John Michael returned 27,380 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Acer Therapeutics Inc. (0001069308) (Issuer)

      11/20/23 5:07:32 PM ET
      $ACER
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Joseph Donald returned 14,285 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Acer Therapeutics Inc. (0001069308) (Issuer)

      11/20/23 5:05:15 PM ET
      $ACER
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACER
    Leadership Updates

    Live Leadership Updates

    See more
    • Acer Therapeutics Reports Q1 2022 Financial Results and Provides Corporate Update

      NEWTON, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the first quarter ended March 31, 2022 and provided an update on the Company's recent corporate developments. "Progress in Q1 2022 was marked by a transformative debt financing in March, with continued advancement toward potential commercial launch of ACER-001 for UCDs and further development of our other pipeline programs," said Chris Schelling, CEO and Founder of Acer. "Our advances

      5/16/22 4:01:00 PM ET
      $ACER
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acer Therapeutics Reports Q4 and Full Year 2021 Financial Results and Provides Corporate Update

      NEWTON, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided an update on the Company's recent corporate developments. "We made significant progress this year in advancing our pipeline programs, including filing of our New Drug Application and key patent issuances for ACER-001, and receipt of two Investigational New Drug application clearances for our ACER-801 proof-of-con

      3/2/22 5:18:18 PM ET
      $ACER
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acer Therapeutics Announces Appointment of Adrian Quartel, M.D., FFPM, as Chief Medical Officer

      NEWTON, Mass., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced the appointment of Adrian Quartel, M.D., FFPM, as Chief Medical Officer. Dr. Quartel will oversee Acer's clinical development, medical affairs, regulatory and other scientific and medical functions. "We are pleased to welcome Dr. Quartel to our experienced leadership team," said Chris Schelling, CEO and Founder of Acer. "Dr. Quartel's proven track record of guiding the clinical development, approval and la

      2/22/22 8:30:00 AM ET
      $ACER
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACER
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Acer Therapeutics Inc. (Amendment)

      SC 13D/A - Acer Therapeutics Inc. (0001069308) (Subject)

      3/30/23 4:20:57 PM ET
      $ACER
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Acer Therapeutics Inc. (Amendment)

      SC 13G/A - Acer Therapeutics Inc. (0001069308) (Subject)

      2/14/23 4:56:26 PM ET
      $ACER
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Acer Therapeutics Inc. (Amendment)

      SC 13D/A - Acer Therapeutics Inc. (0001069308) (Subject)

      12/2/22 4:02:04 PM ET
      $ACER
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACER
    SEC Filings

    See more
    • SEC Form 15-12G filed by Acer Therapeutics Inc.

      15-12G - Acer Therapeutics Inc. (0001069308) (Filer)

      11/30/23 7:30:25 AM ET
      $ACER
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Acer Therapeutics Inc.

      EFFECT - Acer Therapeutics Inc. (0001069308) (Filer)

      11/27/23 12:15:06 AM ET
      $ACER
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Acer Therapeutics Inc.

      EFFECT - Acer Therapeutics Inc. (0001069308) (Filer)

      11/27/23 12:15:05 AM ET
      $ACER
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACER
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • EF Hutton initiated coverage on Acer Therapeutics with a new price target

      EF Hutton initiated coverage of Acer Therapeutics with a rating of Buy and set a new price target of $9.00

      2/2/22 9:03:08 AM ET
      $ACER
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACER
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Acer Therapeutics Shareholders Vote "FOR" the Proposed Merger and Related Proposals

      NEWTON, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today announced that Institutional Shareholder Services Inc. (ISS) and Glass, Lewis & Co. LLC (Glass Lewis) recommended that Acer shareholders vote "FOR" the proposed merger with Zevra Therapeutics, Inc. and the related proposals in the Company's proxy statement and prospectus for the special meeting of its shareholders to be held on November 8, 2023 at 11:00 a.m. Eastern Time. ISS and Glass Lewis are widely recognized a

      11/2/23 8:30:00 AM ET
      $ACER
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lifshitz Law PLLC Announces Investigations of RPT, HT, SMMF, and ACER

      NEW YORK, Sept. 02, 2023 (GLOBE NEWSWIRE) -- RPT Realty (NYSE:RPT) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of RPT to Kimco Realty for 0.6049 of a newly-issued Kimco Realty share for each share of RPT common stock owned. If you are a RPT investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected]. Hersha Hospitality Trust (NYSE:HT) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of HT to KSL Capit

      9/2/23 7:47:00 PM ET
      $ACER
      $HT
      $RPT
      $SMMF
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Real Estate Investment Trusts
      Real Estate
    • Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product

      Proposed acquisition of Acer for $15M in Zevra stock plus Contingent Value Rights (CVRs) and Zevra's purchase of Acer's secured debt in capital efficient structure Zevra to assume commercialization efforts of OLPRUVA™, recently approved for the treatment of urea cycle disorders (UCDs) FDA-approved commercial asset expected to increase and diversify Zevra's revenues OLPRUVA™ commercial operations provide Zevra scale and cost synergies to complement the potential launch of arimoclomol Adds EDSIVO™, a Phase 3 program for vascular Ehlers-Danlos Syndrome (vEDS), to Zevra's rare disease clinical pipeline Zevra to discuss details during conference call today, at 8:30 a.m. ET CELEBRATION, F

      8/31/23 7:30:00 AM ET
      $ACER
      $ZVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACER
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for OLPRUVA issued to ACER THERAPEUTICS INC

      Submission status for ACER THERAPEUTICS INC's drug OLPRUVA (ORIG-1) with active ingredient SODIUM PHENYLBUTYRATE has changed to 'Approval' on 12/22/2022. Application Category: NDA, Application Number: 214860, Application Classification: Type 5 - New Formulation or New Manufacturer

      12/23/22 1:58:04 PM ET
      $ACER
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACER
    Financials

    Live finance-specific insights

    See more
    • Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product

      Proposed acquisition of Acer for $15M in Zevra stock plus Contingent Value Rights (CVRs) and Zevra's purchase of Acer's secured debt in capital efficient structure Zevra to assume commercialization efforts of OLPRUVA™, recently approved for the treatment of urea cycle disorders (UCDs) FDA-approved commercial asset expected to increase and diversify Zevra's revenues OLPRUVA™ commercial operations provide Zevra scale and cost synergies to complement the potential launch of arimoclomol Adds EDSIVO™, a Phase 3 program for vascular Ehlers-Danlos Syndrome (vEDS), to Zevra's rare disease clinical pipeline Zevra to discuss details during conference call today, at 8:30 a.m. ET CELEBRATION, F

      8/31/23 7:30:00 AM ET
      $ACER
      $ZVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SWK Holdings Provides Portfolio Update Highlighting Recent Achievements

      Third Quarter 2022 Financial Results to be Announced in Early November DALLAS, Oct. 18, 2022 /PRNewswire/ -- SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science focused specialty finance company catering to small- and mid-sized commercial-stage companies, today provided an update on the progress and achievements of its borrower partners, including recent transactions and activities. "The second half of 2022 has been an active time for SWK. We have capitalized on our strong underlying business fundamentals to close several transactions, including two $25.0 million financings with Aziyo Biologics and MedMinder," stated Jody Staggs, President and Interim CEO of SWK.

      10/18/22 4:05:00 PM ET
      $ACER
      $AZYO
      $BIOL
      $BTCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical Specialities
      Medical/Dental Instruments
    • SWK Holdings Corporation Announces Financial Results for Fourth Quarter and Full-Year 2021

      Conference Call and Live Audio Webcast Scheduled for Monday, March 28, 2022, at 10:00 a.m. ET Corporate Highlights Reconstituted Board and appointed Wendy DiCicco, Robert K. Hatcher, and Laurie Dotter as independent directorsCompleted four transactions from December 2021 through March 2022, deploying $38.5 millionReceived a $10.7 million cash payment from B&D Dental to successfully resolve long-running non-accrual position. Loan carried at $8.3 millionIn December 2021, subsidiary Enteris received a $5.0 million milestone payment from Cara Therapeutics with SWK retaining $3.0 millionEnteris currently advancing six partner feasibility studiesFinance Receivables Segment Update As of December 31

      3/28/22 7:00:00 AM ET
      $ACER
      $SWKH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Diversified Financial Services
      Finance